Pitcairn Co. grew its stake in shares of Humana Inc. (NYSE:HUM – Free Report) by 23.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,672 shares of the insurance provider’s stock after buying an additional 313 shares during the quarter. Pitcairn Co.’s holdings in Humana were worth $580,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently made changes to their positions in HUM. Raymond James & Associates boosted its position in shares of Humana by 28.7% during the 4th quarter. Raymond James & Associates now owns 101,251 shares of the insurance provider’s stock valued at $46,354,000 after purchasing an additional 22,550 shares in the last quarter. CVA Family Office LLC acquired a new position in Humana in the fourth quarter worth approximately $86,000. Raymond James Financial Services Advisors Inc. raised its position in Humana by 13.8% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,676 shares of the insurance provider’s stock valued at $9,008,000 after acquiring an additional 2,390 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Humana by 2.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,250 shares of the insurance provider’s stock valued at $1,946,000 after acquiring an additional 109 shares during the last quarter. Finally, Ritholtz Wealth Management increased its stake in shares of Humana by 504.3% during the 4th quarter. Ritholtz Wealth Management now owns 4,901 shares of the insurance provider’s stock worth $2,244,000 after purchasing an additional 4,090 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
HUM has been the topic of a number of recent analyst reports. Royal Bank of Canada cut their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. The Goldman Sachs Group lowered their target price on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Truist Financial raised their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research report on Monday, July 15th. Baird R W upgraded Humana to a “hold” rating in a research note on Thursday, May 30th. Finally, UBS Group lowered their target price on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $402.60.
Humana Price Performance
Shares of HUM stock opened at $386.47 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The stock’s fifty day simple moving average is $364.93 and its 200 day simple moving average is $347.13. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The firm has a market cap of $46.57 billion, a price-to-earnings ratio of 24.06, a P/E/G ratio of 2.23 and a beta of 0.51.
Humana (NYSE:HUM – Get Free Report) last posted its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.38 EPS. On average, analysts expect that Humana Inc. will post 16.27 earnings per share for the current fiscal year.
Humana Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
- Five stocks we like better than Humana
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is the Euro STOXX 50 Index?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
- What Investors Need to Know About Upcoming IPOs
- Is Now the Time to Invest? ServiceNow Stock Sent to New Highs
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.